Clinical Trial Update: 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome [Phase 1, Phase 2]

View source ↗

Summary

This trial evaluates a targeted radiopharmaceutical (211At-BC8-B10) followed by an allogeneic donor stem cell transplant for relapsed or refractory high-risk ac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Mixed Phenotype Acute Leukemia
• Myelodysplastic Syndrome
• Myelomonocytic Leukemia

Drugs mentioned

• 211At-BC8-B10 (Astatine-211 labeled BC8-B10 antibody)
• Allogeneic stem cell transplant (Allogeneic hematopoietic stem cell transplantation)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 1, Phase 2 | Status: RECRUITING